A detailed history of Virginia Retirement Systems Et Al transactions in Mirati Therapeutics, Inc. stock. As of the latest transaction made, Virginia Retirement Systems Et Al holds 21,400 shares of MRTX stock, worth $0. This represents 0.01% of its overall portfolio holdings.

Number of Shares
21,400
Previous 6,600 224.24%
Holding current value
$0
Previous $238,000 291.6%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Jan 02, 2024

BUY
$27.8 - $45.35 $411,440 - $671,180
14,800 Added 224.24%
21,400 $932,000
Q2 2023

Aug 22, 2023

BUY
$36.13 - $49.49 $238,458 - $326,634
6,600 New
6,600 $238,000
Q3 2022

May 16, 2023

BUY
$59.5 - $86.7 $226,100 - $329,460
3,800 Added 126.67%
6,800 $475 Million
Q1 2022

Apr 21, 2022

SELL
$75.82 - $150.97 $75,820 - $150,970
-1,000 Reduced 25.0%
3,000 $247,000
Q4 2021

Feb 03, 2022

BUY
$132.01 - $190.29 $528,040 - $761,160
4,000 New
4,000 $587,000
Q3 2021

Oct 21, 2021

SELL
$132.13 - $177.45 $396,390 - $532,350
-3,000 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$144.0 - $179.73 $72,000 - $89,865
-500 Reduced 14.29%
3,000 $485,000
Q1 2021

Apr 30, 2021

BUY
$158.92 - $221.61 $79,460 - $110,805
500 Added 16.67%
3,500 $600,000
Q4 2020

Feb 16, 2021

SELL
$162.05 - $240.27 $64,820 - $96,108
-400 Reduced 11.76%
3,000 $659,000
Q3 2020

Nov 12, 2020

SELL
$113.26 - $167.27 $147,238 - $217,451
-1,300 Reduced 27.66%
3,400 $565,000
Q2 2020

Aug 12, 2020

SELL
$72.01 - $120.39 $21,603 - $36,117
-300 Reduced 6.0%
4,700 $537,000
Q1 2020

May 12, 2020

BUY
$69.78 - $116.21 $348,900 - $581,050
5,000 New
5,000 $384,000

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Virginia Retirement Systems Et Al Portfolio

Follow Virginia Retirement Systems Et Al and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virginia Retirement Systems Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Virginia Retirement Systems Et Al with notifications on news.